Max Colao, OncoVerity CEO

Tiny mul­ti­omics biotech se­cures for­mer J&J drug, new ex­ecs and new fi­nanc­ing

A new spin­out from Bel­gium’s ar­genx seeks to give new life to a can­di­date once in-li­censed to J&J.

On­coVer­i­ty an­nounced Mon­day af­ter­noon that it had in-li­censed cusat­uzum­ab from ar­genx. The biotech al­so ap­point­ed two new C-suite ex­ec­u­tives and se­cured a $30 mil­lion Se­ries A round.

CEO Max Co­lao joins On­coVer­i­ty af­ter work­ing as Au­rinia’s com­mer­cial chief, and stints at Alex­ion and Am­gen. New CMO Clay Smith has been as­so­ciate chief of the Uni­ver­si­ty of Col­orado’s hema­tol­ogy di­vi­sion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.